<DOC>
	<DOC>NCT01138579</DOC>
	<brief_summary>This study is an investigator driven, open-label, non-randomized, uncontrolled, dose escalating Phase I/II study evaluating the safety and preliminary efficacy of the trifunctional bispecific antibody FBTA05 in combination with donor lymphocyte infusions (DLI) for treatment of relapsed or refractory disease in CD20 positive either low- or high-grade non-Hodgkin´s lymphoma after allogeneic transplantation</brief_summary>
	<brief_title>Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patient´s written informed consent ≥ 18 years of age; male and female Confirmed CLL, low grade NHL or high grade NHL on standard histological or immunophenotypical criteria described in the WHO classification of lymphoid malignancies CD20 positivity (if not already confirmed) Adequate haematological, liver and kidney functions Platelet count ≥25,000mm³ (=25 x 10^9/l) Patients with active disease (relapsed/refractory) that survived at least 60 days after allogeneic transplantation Eastern Cooperative Oncology Group (ECOG) performance status &lt;=2 (Appendix IV) Negative pregnancy test (no more than 2 days before enrolment) and adequate contraception during the study in women of child bearing potential (pre menopausal, &lt;2 years postmenopausal or not surgically sterile) Any antiCD20 and / or any other antiT cell directed antibody treatments &lt; 3 months before application of FBTA05 Positivity for human antimouse antibodies (HAMAs) History of GvHD ° III or IV, or GvHD requiring steroid therapy with more than 10 mg/day Known or suspected hypersensitivity to recombinant, murine or rat proteins AST/SGOT greater than 10 x ULN (grade 3, CTCAE) Bilirubin greater than 5 x ULN (grade 3, CTCAE) Creatinine greater than 3.5 mg/dl (grade 3, CTCAE) Acute or uncontrolled chronic infections, viral infections at risk of reactivation (e.g.HCV, HBV, HIV) Unable or unwilling to comply fully with the protocol Any condition which in the judgement of the Investigator would place the subject at undue risk or interfere with the results of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>FBTA05</keyword>
	<keyword>CD20</keyword>
	<keyword>CLL</keyword>
	<keyword>NHL</keyword>
	<keyword>DLI</keyword>
	<keyword>allogeneic transplantation</keyword>
	<keyword>CD20 positive chronic lymphocytic leukemia (CLL)</keyword>
	<keyword>low and high grade non-Hodgkin´s lymphoma (NHL) after allogeneic stem cell transplantation with active disease</keyword>
</DOC>